Spire Healthcare (SPI) AI Stock Analysis

• Market Cap: £770.94M
• Dividend Yield: 1.37%
• Average Volume (3M): 1.66M
• Price to Earnings (P/E): 40.8
• Beta (1Y): 0.78
• Revenue Growth: 6.95%
• EPS Growth: -34.38%
• Country: UK
• Employees: 15,703
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 402,759,600
• 10 Day Avg. Volume: 559,423
• 30 Day Avg. Volume: 1,661,785
• PEG Ratio: -1.17
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.42
• P/FCF Ratio: 4.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £275.00
• Price Target Upside: 62.72% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 0.1
• Revenue Forecast (FY): £1.63B

• Rating: 54 Neutral
• Price Target: 195.00 p ▲(15.38% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is primarily supported by solid revenue recovery and consistently positive cash generation, but is held back by high leverage and weak net income conversion. Technicals are soft with the price below key moving averages, and valuation looks stretched with a high P/E and modest yield.

Positive Factors

Revenue Growth

Multi-year revenue expansion from ~£0.92B to ~£1.58B (2020–2025) demonstrates sustained demand recovery across private, self-pay and NHS contracts. Durable volume and pricing improvements boost hospital utilization and provide revenue visibility and resilience over the next 2–6 months.

Cash Generation

Consistent improvement in operating cash flow (to ~£219M) and meaningful free cash flow (~£143M) reflect strong core cash conversion. Reliable cash generation supports debt servicing, routine capex and selective reinvestment, underpinning operational flexibility and financial durability.

Operating Margin Stability

Stable operating margins (c.8–9%) and mid-teens EBITDA margins indicate solid underlying unit economics across sites. This steadiness in operating profitability gives the business a structural ability to absorb cost fluctuations and sustain cash flows even if volumes vary moderately.

Negative Factors

High Leverage

A debt-to-equity ratio of roughly 1.6–1.8 leaves the company highly leveraged for the sector. Elevated leverage increases sensitivity to rising rates and refinancing risk, reduces strategic flexibility for M&A or capex, and narrows the margin for error if operations or cash flows weaken.

Thin Net Margins

Very thin net margin (~1% in 2025) and declining net income signal weak bottom-line conversion despite solid operating performance. Pressure from interest, tax or exceptional items limits retained earnings, constrains reinvestment capacity and reduces the buffer against future earnings shocks.

Moderate Cash Coverage

Free cash flow has not consistently exceeded reported earnings and coverage ratios (~0.56–0.69) are moderate. That limited headroom weakens the company’s ability to rapidly de-lever, fund growth or absorb prolonged demand downturns without relying on external financing or cost-cutting measures.

Spire Healthcare Business Overview & Revenue Model

Company Description

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular surgery, weight loss, and women's health. Further, the company offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. It offers diagnostics, in-patient, daycase, and out-patient care services through 40 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Spire Healthcare generates revenue primarily through patient care services provided in its hospitals and clinics. The company's revenue model includes income from private medical insurance, self-pay patients, and NHS contracts for services. Key revenue streams include elective surgeries, outpatient consultations, and diagnostic services. Significant partnerships with private health insurers and NHS frameworks enable Spire to secure a steady flow of patients and revenue. Additionally, the company benefits from a growing demand for private healthcare services, driven by factors such as increasing patient awareness, longer waiting times in the NHS, and a trend towards personalized medical care.

Spire Healthcare Financial Statement Overview

Summary

Strong multi-year revenue growth and consistently positive operating/free cash flow support the business. However, high leverage (debt well above equity) and very thin net margins (~1% in 2025) limit returns and reduce resilience, keeping the score in the mid-range.

Income Statement

Revenue has expanded strongly since 2020 (from ~£0.92B to ~£1.58B in 2025), showing a solid recovery and demand backdrop. Operating profitability is reasonably steady with operating margin around ~8–9% over the last four years, and EBITDA margin broadly stable in the mid-teens. The key weakness is bottom-line conversion: net margin remains thin (about ~1.0% in 2025) and net income fell versus 2024, indicating higher costs/interest/taxes are pressuring reported earnings despite stable operating performance.

Balance Sheet

The balance sheet is leveraged for the sector, with debt running well above equity (debt-to-equity roughly ~1.6–1.8 across 2020–2025). Equity has been broadly stable, but returns on equity are low (low-single-digits in recent years, and negative in 2020–2021), reflecting limited earnings power relative to the capital base. While assets have grown gradually, the combination of high leverage and modest profitability leaves less cushion if operating conditions soften or financing costs rise.

Cash Flow

Cash generation is a relative strength: operating cash flow has been consistently positive and improved from ~£142M (2020) to ~£219M (2025). Free cash flow is also consistently positive and grew meaningfully in 2025 (~£143M), supporting debt service and reinvestment capacity. The main concern is that free cash flow has not consistently exceeded reported earnings (free cash flow is ~65% of net income in 2025), and cash flow coverage versus obligations appears only moderate (coverage ratio ~0.56–0.69 historically), suggesting limited headroom if cash flows weaken.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.58B	1.51B	1.36B	1.20B	1.11B
Gross Profit	599.10M	683.60M	520.60M	440.50M	394.10M
EBITDA	262.50M	250.40M	231.20M	193.30M	182.20M
Net Income	16.40M	25.40M	27.30M	8.60M	-9.70M
Balance Sheet
Total Assets	2.38B	2.34B	2.29B	2.16B	2.24B
Cash, Cash Equivalents and Short-Term Investments	34.70M	43.70M	49.60M	74.20M	202.60M
Total Debt	1.32B	1.28B	1.26B	1.19B	1.27B
Total Liabilities	1.63B	1.60B	1.55B	1.43B	1.53B
Stockholders Equity	742.80M	748.40M	739.90M	731.00M	709.60M
Cash Flow
Free Cash Flow	143.00M	123.60M	115.50M	72.80M	101.30M
Operating Cash Flow	219.30M	235.70M	199.90M	160.50M	170.60M
Investing Cash Flow	-90.40M	-99.00M	-157.20M	-98.00M	-48.30M
Financing Cash Flow	-135.40M	-145.10M	-82.90M	-190.90M	-26.00M

Spire Healthcare Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 169.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SPI, the sentiment is Negative. The current price of 169 is below the 20-day moving average (MA) of 198.68, below the 50-day MA of 190.36, and below the 200-day MA of 211.01, indicating a neutral trend. The MACD of -0.38 indicates Positive momentum. The RSI at 43.75 is Neutral, neither overbought nor oversold. The STOCH value of 39.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SPI.

Spire Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NIOX	68 Neutral	£263.30M	11.85	6.70%	3.40%	17.95%	-54.68%
CRW	61 Neutral	£530.74M	22.56	6.00%	1.66%	5.74%	63.23%
PRTC	55 Neutral	£298.88M	-2.25	15.04%	―	1231.50%	―
SPI	54 Neutral	£770.94M	40.77	2.51%	1.37%	6.95%	-34.38%
OPT	53 Neutral	£162.02M	41.48	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AGY	45 Neutral	£728.24M	-9.44	―	―	-0.28%	22.94%

Spire Healthcare Corporate Events

Spire Healthcare Delivers Resilient 2025 Results but Warns on NHS Revenue Hit in 2026

Spire Healthcare reported a resilient 2025 performance, with revenue up 4.5% to £1.58bn and adjusted EBITDA rising 3.2%, as £30m of transformation-driven cost savings and tight capex control lifted adjusted free cash flow by nearly 65%. While adjusted profit before tax fell 7.4% and reported profit was hit by restructuring and Strategic Review costs, the group maintained margins in its hospital division, increased adjusted EPS and recommended a reduced final dividend, signalling ongoing shareholder returns despite cost headwinds.

Operationally, the company completed a major centralisation of administration into Patient Support Centres and implemented a leaner staffing model, reducing around 400 roles to improve flexibility and efficiency. It continued to expand its primary care footprint with acquisitions in occupational health and physiotherapy and new outpatient-led clinics that are already generating referrals into hospitals, supporting growth in private patient volumes.

Spire also focused on reinforcing its quality and brand, retaining strong regulator-equivalent ratings, securing high patient and consultant satisfaction and investing further in robotics and AI-enabled MRI capacity, which has helped it achieve sector-leading awareness and consideration scores. These moves underpin its strategy to capture rising private demand amid pressure on the NHS, with 70% of hospital revenue now from private payors and early 2026 trends showing improved private revenue growth.

Looking ahead, the group faces a sharp, expected fall of about 25% in NHS revenue in the first quarter of 2026 due to commissioning cuts and Activity Management Plans, creating near-term uncertainty over public-funded volumes. Management is responding with additional transformation savings beyond its original £30m target to offset the NHS impact, while awaiting the reset of NHS commissioning plans from April and banking on continued private sector growth to support its medium-term outlook.

The most recent analyst rating on (GB:SPI) stock is a Hold with a £214.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Spire Healthcare Wins Deadline Extension for Potential Takeover Bids

Spire Healthcare has secured an extension to the deadline for potential bidders Bridgepoint Advisers and Triton Investment Advisers to decide whether to make a takeover offer, pushing the cut-off from 21 February to 21 March 2026. The move follows ongoing talks as part of the company’s strategic review that began in September 2025 and keeps Spire in an offer period, ensuring takeover disclosure rules continue to apply for investors.

The extension signals continuing interest from private equity suitors but offers no guarantee that a firm bid will emerge or on what terms, leaving shareholders and other stakeholders facing a further period of uncertainty. The process underscores Spire’s strategic importance in the U.K. healthcare market and keeps open the possibility of a significant change in ownership or capital structure, which could reshape its long-term positioning and governance.

The most recent analyst rating on (GB:SPI) stock is a Hold with a £214.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Spire Healthcare Confirms Preliminary Takeover Talks With Bridgepoint and Triton

Spire Healthcare has confirmed that private equity firms Bridgepoint Advisers and Triton Investment Advisers are among the parties in preliminary talks with the company as part of the strategic review launched in September 2025, following recent media speculation. The discussions may or may not lead to a formal takeover offer, with both suitors facing a regulatory deadline of 21 February 2026 to either announce a firm intention to bid or walk away under UK takeover rules, underscoring the possibility of significant corporate change for the FTSE 250 healthcare group but with no certainty yet for shareholders, staff or other stakeholders.

The most recent analyst rating on (GB:SPI) stock is a Hold with a £187.00 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.

Spire Healthcare Non-Executive Director Jill Anderson Joins Croda International Board

Spire Healthcare has announced that non-executive director Jill Anderson has been appointed to the board of Croda International as a non-executive director, where she will also serve on the audit, nomination and remuneration committees from 12 January 2026. The additional blue-chip board role is likely to broaden Anderson’s external experience and networks, potentially enhancing governance insight at Spire as it maintains its position as a major independent provider of acute and specialist healthcare services across the UK.

The most recent analyst rating on (GB:SPI) stock is a Buy with a £2.75 price target. To see the full list of analyst forecasts on Spire Healthcare stock, see the GB:SPI Stock Forecast page.